Some Pyridoxal Analogs and Their Transamination with Amino Acids Jerry David Albert Iowa State University
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pyridoxal Phosphate Is Better Than Pyridoxine for Controlling Idiopathic Intractable Epilepsy
512 ORIGINAL ARTICLE Arch Dis Child: first published as 10.1136/adc.2003.045963 on 25 April 2005. Downloaded from Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy H-S Wang, M-F Kuo, M-L Chou, P-C Hung, K-L Lin, M-Y Hsieh, M-Y Chang ............................................................................................................................... Arch Dis Child 2005;90:512–515. doi: 10.1136/adc.2003.045963 Aim: To study the difference between pyridoxine (PN) and its active form, pyridoxal phosphate, (PLP) in control of idiopathic intractable epilepsy in children. Methods: Among 574 children with active epilepsy, 94 (aged 8 months to 15 years) were diagnosed with idiopathic intractable epilepsy for more than six months. All received intravenous PLP 10 mg/kg, then 10 mg/kg/day in four divided doses. If seizures recurred within 24 hours, another dose of 40 mg/kg was See end of article for given, followed by 50 mg/kg/day in four divided doses. For those patients whose seizures were totally authors’ affiliations controlled, PLP was replaced by the same dose of oral PN. If the seizure recurred, intravenous PLP was ....................... infused followed by oral PLP 50 mg/kg/day. Correspondence to: Results: Fifty seven patients had generalised seizures (of whom 13 had infantile spasms) and 37 had focal Dr M-F Kuo, Division of seizure. Eleven had dramatic and sustained responses to PLP; of these, five also responded to PN. Within (Pediatric) Neurosurgery, six months of treatment with PLP or PN, five of the 11 patients were seizure free and had their previous Department of Surgery, National Taiwan University antiepileptic medicine tapered off gradually. -
Detection and Formation Scenario of Citric Acid, Pyruvic Acid, and Other Possible Metabolism Precursors in Carbonaceous Meteorites
Detection and formation scenario of citric acid, pyruvic acid, and other possible metabolism precursors in carbonaceous meteorites George Coopera,1, Chris Reeda, Dang Nguyena, Malika Cartera, and Yi Wangb aExobiology Branch, Space Science Division, National Aeronautics and Space Administration-Ames Research Center, Moffett Field, CA 94035; and bDevelopment, Planning, Research, and Analysis/ZymaX Forensics Isotope, 600 South Andreasen Drive, Suite B, Escondido, CA 92029 Edited by David Deamer, University of California, Santa Cruz, CA, and accepted by the Editorial Board July 1, 2011 (received for review April 12, 2011) Carbonaceous meteorites deliver a variety of organic compounds chained three-carbon (3C) pyruvic acid through the eight-carbon to Earth that may have played a role in the origin and/or evolution (8C) 7-oxooctanoic acid and the branched 6C acid, 3-methyl- of biochemical pathways. Some apparently ancient and critical 4-oxopentanoic acid (β-methyl levulinic acid), Fig. 1, Table S1. metabolic processes require several compounds, some of which 2-methyl-4-oxopenanoic acid (α-methyl levulinic acid) is tenta- are relatively labile such as keto acids. Therefore, a prebiotic setting tively identified (i.e., identified by mass spectral interpretation for any such individual process would have required either a only). As a group, these keto acids are relatively unusual in that continuous distant source for the entire suite of intact precursor the ketone carbon is located in a terminal-acetyl group rather molecules and/or an energetic and compact local synthesis, parti- than at the second carbon as in most of the more biologically cularly of the more fragile members. -
Composition: Each
______________________________________________________________________________________________________________ Composition: Each Tablet Contains L-Methylfolate 1mg Mecobalamin 1500 mcg Pyridoxal 5’-phosphate 0.5mg Pharmacokinetic properties: L-methylfolate is a water soluble molecule which is primarily excreted via the kidneys. In a study of subjects with coronary artery disease (n=21), peak plasma levels were reached in 1-3 hours following ORAL/PARENTERAL administration. Peak concentrations of L-methylfolate were found to be more than seven times higher than folic acid (129 ng ml-1 vs. 14.1 ng ml-1) following ORAL/PARENTERAL administration. The mean elimination half-life is approximately 3 hours after 5mg of oral L- methylfolate, administered daily for 7 days. The mean values for Cmax, Tmax, and AUC0-12 were 129 ng ml-1, 1.3 hr., and 383 respectively. Red blood cells (RBCs) appear to be the storage depot for folate, as RBC levels remain elevated for periods in excess of 40 days following discontinuation of supplementation. Plasma protein binding studies showed that L-methylfolate is 56% bound to plasma proteins. Mecobalamin substances bind to intrinsic factor; a glycoprotein secreted by the gastric mucosa, and are then actively absorbed from the gastrointestinal tract. Absorption is impaired in patients with an absence of intrinsic factor, with a malabsorption syndrome or with disease or abnormality of the gut, or after gastrectomy. Absorption from the gastrointestinal tract can also occur by passive diffusion; little of the vitamin present in food is absorbed in this manner although the process becomes increasingly important with larger amounts such as those used therapeutically. After intranasal dosage, peak plasma concentrations of cyanocobalamin have been reached in 1 to 2 hours. -
Lecture: 28 TRANSAMINATION, DEAMINATION and DECARBOXYLATION
Lecture: 28 TRANSAMINATION, DEAMINATION AND DECARBOXYLATION Protein metabolism is a key physiological process in all forms of life. Proteins are converted to amino acids and then catabolised. The complete hydrolysis of a polypeptide requires mixture of peptidases because individual peptidases do not cleave all peptide bonds. Both exopeptidases and endopeptidases are required for complete conversion of protein to amino acids. Amino acid metabolism The amino acids not only function as energy metabolites but also used as precursors of many physiologically important compounds such as heme, bioactive amines, small peptides, nucleotides and nucleotide coenzymes. In normal human beings about 90% of the energy requirement is met by oxidation of carbohydrates and fats. The remaining 10% comes from oxidation of the carbon skeleton of amino acids. Since the 20 common protein amino acids are distinctive in terms of their carbon skeletons, amino acids require unique degradative pathway. The degradation of the carbon skeletons of 20 amino acids converges to just seven metabolic intermediates namely. i. Pyruvate ii. Acetyl CoA iii. Acetoacetyl CoA iv. -Ketoglutarate v. Succinyl CoA vi. Fumarate vii. Oxaloacetate Pyruvate, -ketoglutarate, succinyl CoA, fumarate and oxaloacetate can serve as precursors for glucose synthesis through gluconeogenesis.Amino acids giving rise to these intermediates are termed as glucogenic. Those amino acids degraded to yield acetyl CoA or acetoacetate are termed ketogenic since these compounds are used to synthesize ketone bodies. Some amino acids are both glucogenic and ketogenic (For example, phenylalanine, tyrosine, tryptophan and threonine. Catabolism of amino acids The important reaction commonly employed in the breakdown of an amino acid is always the removal of its -amino group. -
Aqueous Phase Photochemistry of Α-Keto Acids As a Function of Ph
Aqueous Phase Photochemistry of α-Keto Acids as a Function of pH Michael Ryan Dooley Department of Chemistry and Biochemistry University of Colorado at Boulder March 21 2017 Advisor: Dr. Veronica Vaida, Department of Chemistry and Biochemistry Committee: Dr. Veronica Vaida, Department of Chemistry and Biochemistry Dr. Robert Parson, Department of Chemistry and Biochemistry Dr. Chris Bowman, Department of Chemical and Biological Engineering 1 Tables of Contents Abstract……………………………………………………………………………………..page 2 Introduction…………………………………………………………………………………page 2 Experimental Methods………………………………………………………………….…..page 9 Materials……………………………………………………………………….……page 9 Titration – Debye-Huckel Extended Method……………………………………….page 9 Photolysis of Pyruvic Acid……………………………...…………………………page 11 Ultraviolet-Visible Spectroscopy……………………………………….…………page 12 1HNMR…………………………………………………………………………….page 12 Electrospray Ionization Mass Spectrometry……………..………………………...page 13 Results and Discussion…………………………………………...………………..………page 13 Determination of Acid Dissociation Constants…………………………………….page 13 Dependence of Keto-Diol Ratio on pH…………………………………………….page 16 Dark Processing of Pre-Photolysis Solutions…………………………………..….page 18 Photolysis of Pyruvic Acid………………………………….……………………..page 21 Conclusions and Future Directions…………...…………………………………………....page 27 References…………………………………………………………………….……………page 29 2 Abstract α-Keto acids react in solution in the presence of sunlight to form complex organic oligomers that can contribute to the formation of organic atmospheric aerosols. -
Vitamin B6 Metabolism and Regulation of Pyridoxal Kinase
Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2009 VITAMIN B6 METABOLISM AND REGULATION OF PYRIDOXAL KINASE Amit Gandhi Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Chemicals and Drugs Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2008 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Amit K. Gandhi 2009 All Rights Reserved VITAMIN B 6 METABOLISM AND REGULATION OF PYRIDOXAL KINASE A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. By AMIT K. GANDHI M.S (Pharmaceutical Science), Rajiv Gandhi University, Indore, India, 2003 B.Pharm, Rajiv Gandhi University, Indore, India, 2001 Director: Martin K. Safo, Ph.D Assistant Professor, Department of Medicinal Chemistry Virginia Commonwealth University Richmond, Virginia December, 2009 Acknowledgement I would like to take this opportunity to express my deep gratitude and profound respect to my advisor, Dr. Martin K. Safo, for his supervision, advice, and guidance in this research work. His support and insight have been invaluable in the progression of my research. I also appreciate his words of encouragement, which kept me always in an innovative mood and guided me at all the times to bring about the best in me. He is my mentor and teacher whom I shall remember forever. -
Transamination in Tumors, Fetal Tissues, and Regenerating Liver* Philip P
Transamination in Tumors, Fetal Tissues, and Regenerating Liver* Philip P. Cohen, M.D., and G. Leverne Hekhuis (From the Laboratory o~ Physiological Chemistry, Yale University School of Medicine, New Haven, Connecticut) (Received for publication June 9, I94I) von Euler and co-workers (22), on the basis of TISSUE SOURCES results of essentially qualitative experiments, first re- Tumors.--The mouse tumors employed in this in- ported that the transaminase activity ot~ tumors was vestigation were the following: low. These investigators, using Jensen sarcoma and normal muscle, measured the rate of disappearance of I. United States Public Health Service No. ~7-- oxaloacetic acid in the following reaction: originally described as a neuroepithelioma (20). 1 2. Sarcoma 37 .1 3. Yale No. xuan estrogen-induced ,) 1( + )-glutamic acid + oxaloacetic acid a mammary adenocarcinoma (5). 1 4. No. x5o9I-A - ~'b a-ketoglutaric acid + aspartic acid spontaneous mammary medullary adenocarcinoma In addition to studies of reaction I in tumors, Braun- (6) "1 5- No. 42--glioblastoma multiforme. 2 6. No. stein and Azarkh (2) studied the reaction: i o8--rhabdomyosarcoma. 2 The tumors were transplanted at regular intervals 2) glutamic acid+a-keto acid to insure a uniform supply. a-ketoglutaric acid + amino acid "-b- Fetal, kitten, and adult cat tissues.--Two pregnant cats provided the fetal tissue. The length of the preg- The amino acids investigated in the case of reaction nancy was uncertain, but was estimated to be in the 2b were the d- and l-forms of alanine, valine, leucine, last trimester in both instances. Hemihysterectomies and isoleucine. The rate of reaction za in which both were performed under nembutal anesthesia and 2 d(--)- and l(+)-glutamic acid were used, plus fetuses removed from each animal. -
Lecture 11 - Biosynthesis of Amino Acids
Lecture 11 - Biosynthesis of Amino Acids Chem 454: Regulatory Mechanisms in Biochemistry University of Wisconsin-Eau Claire 1 Introduction Biosynthetic pathways for amino acids, Text nucleotides and lipids are very old Biosynthetic (anabolic) pathways share common intermediates with the degradative (catabolic) pathways. The amino acids are the building blocks for proteins and other nitrogen-containing compounds 2 2 Introduction Nitrogen Fixation Text Reducing atmospheric N2 to NH3 Amino acid biosynthesis pathways Regulation of amino acid biosynthesis. Amino acids as precursors to other biological molecules. e.g., Nucleotides and porphoryns 3 3 Introduction Nitrogen fixation is carried out by a few Text select anaerobic micororganisms The carbon backbones for amino acids come from glycolysis, the citric acid cycle and the pentose phosphate pathway. The L–stereochemistry is enforced by transamination of α–keto acids 4 4 1. Nitrogen Fixation Microorganisms use ATP and ferredoxin to Text reduce atmospheric nitrogen to ammonia. 60% of nitrogen fixation is done by these microorganisms 15% of nitrogen fixation is done by lighting and UV radiation. 25% by industrial processes Fritz Habers (500°C, 300!atm) N2 + 3 H2 2 N2 5 5 1. Nitrogen Fixation Enzyme has both a reductase and a Text nitrogenase activity. 6 6 1.1 The Reductase (Fe protein) Contains a 4Fe-4S Text center Hydrolysis of ATP causes a conformational change that aids the transfer of the electrons to the nitrogenase domain (MoFe protein) 7 7 1.1 The Nitrogenase (MoFe Protein) The nitrogenase Text component is an α2β2 tetramer (240#kD) Electrons enter the P-cluster 8 8 1.1 The Nitrogenase (MoFe Protein) An Iron-Molybdenum cofactor for the Text nitrogenase binds and reduces the atmospheric nitrogen. -
Phosphate-Dependent Enzymes Involved in Biotin Biosynthesis: Structure, Reaction Mechanism and Inhibition☆
Biochimica et Biophysica Acta 1814 (2011) 1459–1466 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbapap Review Pyridoxal-5′-phosphate-dependent enzymes involved in biotin biosynthesis: Structure, reaction mechanism and inhibition☆ Stéphane Mann, Olivier Ploux ⁎ Laboratoire Charles Friedel, ENSCP Chimie ParisTech, UMR CNRS 7223, 11 rue Pierre et Marie Curie, F-75231 Paris Cedex 05, France article info abstract Article history: The four last steps of biotin biosynthesis, starting from pimeloyl-CoA, are conserved among all the Received 5 July 2010 biotin-producing microorganisms. Two enzymes of this pathway, the 8-amino-7-oxononanoate synthase Received in revised form 4 November 2010 (AONS) and the 7,8-diaminopelargonic acid aminotransferase (DAPA AT) are dependent on pyridoxal-5′- Accepted 10 December 2010 phosphate (PLP). This review summarizes our current understanding of the structure, reaction mechanism Available online 21 December 2010 and inhibition on these two interesting enzymes. Mechanistic studies as well as the determination of the crystal structure of AONS have revealed a complex mechanism involving an acylation with inversion of Keywords: fi fi 8-amino-7-oxononanoate synthase con guration and a decarboxylation with retention of con guration. This reaction mechanism is shared by the 7,8-diaminopelargonic acid aminotransferase homologous 5-aminolevulinate synthase and serine palmitoyltransferase. While the reaction catalyzed by Pyridoxal-5′-phosphate DAPA AT is a classical PLP-dependent transamination, the inactivation of this enzyme by amiclenomycin, a Enzyme reaction mechanism natural antibiotic that is active against Mycobacterium tuberculosis, involves the irreversible formation of an Inhibition adduct between PLP and amiclenomycin. -
Large-Scale Domain Motions and Pyridoxal-5'-Phosphate Assisted Radical Catalysis in Coenzyme † B12-Dependent Aminomutases
Int. J. Mol. Sci. 2014, 15, 3064-3087; doi:10.3390/ijms15023064 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Large-Scale Domain Motions and Pyridoxal-5'-Phosphate Assisted Radical Catalysis in Coenzyme † B12-Dependent Aminomutases Amarendra Nath Maity, Yung-Han Chen and Shyue-Chu Ke * Physics Department, National Dong Hwa University, Hualien 97401, Taiwan; E-Mails: [email protected] (A.N.M.); [email protected] (Y.-H.C.) † This paper is dedicated to Emeritus Professor Perry A. Frey (Biochemistry Department, University of Wisconsin at Madison, Madison, WI, USA) on the occasion of his 78th birthday. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +886-3863-3705; Fax: +886-3863-3690. Received: 27 November 2013; in revised form: 25 December 2013 / Accepted: 22 January 2014 / Published: 20 February 2014 Abstract: Lysine 5,6-aminomutase (5,6-LAM) and ornithine 4,5-aminomutase (4,5-OAM) are two of the rare enzymes that use assistance of two vitamins as cofactors. These enzymes employ radical generating capability of coenzyme B12 (5'-deoxyadenosylcobalamin, dAdoCbl) and ability of pyridoxal-5'-phosphate (PLP, vitamin B6) to stabilize high-energy intermediates for performing challenging 1,2-amino rearrangements between adjacent carbons. A large-scale domain movement is required for interconversion between the catalytically inactive open form and the catalytically active closed form. In spite of all the similarities, these enzymes differ in substrate specificities. 4,5-OAM is highly specific for D-ornithine as a substrate while 5,6-LAM can accept D-lysine and L-β-lysine. -
Prediagnostic Plasma Pyridoxal 5 -Phosphate (Vitamin B6) Levels
Published OnlineFirst August 9, 2012; DOI: 10.1158/1055-9965.EPI-12-0717-T Cancer Epidemiology, Research Article Biomarkers & Prevention Prediagnostic Plasma Pyridoxal 50-Phosphate (Vitamin B6) Levels and Invasive Breast Carcinoma Risk: The Multiethnic Cohort Galina Lurie1, Lynne R. Wilkens1, Yurii B. Shvetsov1, Nicholas J. Ollberding2, Adrian A. Franke1, Brian E. Henderson3, Laurence N. Kolonel1, and Marc T. Goodman1 Abstract Background: Evidence from experimental and epidemiologic studies suggests that vitamin B6 may reduce the risk of breast cancer. Methods: We examined the association of prediagnostic plasma concentrations of pyridoxal-50-phosphate (PLP), an active form of vitamin B6, with postmenopausal breast cancer risk in a case–control study nested in the multiethnic cohort in Hawaii and Southern California, including 706 cases and 706 controls matched on date of birth, ethnicity, study site, date of blood draw, time of blood draw, hours of fasting before blood draw, and use of menopausal hormones. OR and 95% confidence intervals (CI) were calculated using conditional logistic regression models. Results: Women with plasma PLP concentrations in the highest quartile had a 30% reduced risk of invasive breast cancer (CI: 0.50–0.98) as compared with the women in the lowest PLP quartile (P for trend ¼ 0.02). The association seemed to be limited in cases with hormone receptor-positive tumors (P for heterogeneity ¼ 0.04); and remained unchanged in the analysis restricted to women with blood samples collected more than one year before cancer diagnosis (OR ¼ 0.69; CI: 0.48–0.99; P for trend ¼ 0.03). Conclusions: These data suggest that higher circulating levels of vitamin B6 are associated with a reduced risk of invasive postmenopausal breast cancer. -
Summary Report
Pyridoxal 5-Phosphate: Summary Report Item Type Report Authors Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Yuen, Melissa V.; Mattingly, Ashlee N. Publication Date 2019-12 Keywords Pyridoxal; Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration; Pyridoxal Phosphate Rights Attribution-NoDerivatives 4.0 International Download date 02/10/2021 21:53:32 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12348 Summary Report Pyridoxal 5-Phosphate Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy December 2019 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATION ..................................................................................................... 4 METHODOLOGY ...................................................................................................................